Evogene (NASDAQ:EVGN) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Evogene (NASDAQ:EVGN) in a research note issued to investors on Thursday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Lake Street Capital reduced their price target on Evogene from $30.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, August 23rd.

Evogene Stock Performance

Shares of Evogene stock opened at $1.33 on Thursday. The stock’s 50-day moving average is $2.02 and its 200-day moving average is $3.90. Evogene has a one year low of $1.26 and a one year high of $10.40.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Evogene stock. Renaissance Investment Group LLC purchased a new stake in Evogene Ltd. (NASDAQ:EVGN) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. 10.40% of the stock is currently owned by institutional investors and hedge funds.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.